Additionally, Lee et al. [194] utilized an IL15 superagonist, PD-L1 blockade and the tumor-targeted immunocytokine NHS-IL12 to improve the antitumor efficacies of neoantigen vaccines. This evidence concerns the gene CD274 and neoplasm.